Fresenius Group Overview

Financial Results

To archive

Q3/21 Results

Fresenius improves FY/21 Group guidance for the second time after good Q3 results

  • Fresenius Medical Care with stronger than projected COVID-19 related headwind

  • Fresenius Kabi improves EBIT  outlook; North America returning to growth; Emerging Markets business with continued healthy financial performance

  • Helios Germany with ongoing upward trend for elective treatments; activity levels at Helios Spain above pre-pandemic levels

  • Fresenius Vamed with good performance in the service business; order book in the project business remains at all-time high

  • Cost and efficiency program on track; savings targets confirmed for FY/23

  • Fresenius raises FY/21 Group sales outlook; earnings now expected to be around the top-end of guidance

Selected Key Figures Q3/2021

Sales

€ 9324 m

+5% 1

Q3/20: €8,918 m

EBIT 2

€ 1041 m

-6% 1

Q3/20: €1,113 m

Net Income 2, 3

€ 435 m

+2% 1

Q3/20: €427 m

Earnings per Share 2, 3

€ 0.78

+1% 1

Q3/20: €0.77

1 In constant currency
2 Before special items
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA
 

Sales by business segment

 

€ in millions

 Q3/21

 Q3/20

Change

Organic
sales
growth
Currency translation effects Acqui-sitions Divesti-tures % of total sales1

Fresenius Medical Care

4,442 4,414 1% 1% 0% 1% 1% 47%

Fresenius
Kabi

1,854 1,694 9% 8% 1% 0% 0% 20%

Fresenius Helios

2,622 2,400 9% 5% 1% 5% 0% 28%
Fresenius Vamed 516 517 0% 0% 0% 0% 0% 5%

Total

9,324 8,918 5% 3% 0% 2% 0% 100 %

1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.

Archive